HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TNFα from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis.

Abstract
Bronchiolitis obliterans syndrome is characterized by fibrotic obliteration of small airways which severely impairs graft function and survival after lung transplantation. Bronchial epithelial cells from the transplanted lung can undergo epithelial to mesenchymal transition and this can be accentuated by activated macrophages. Macrophages demonstrate significant plasticity and change phenotype in response to their microenvironment. In this study we aimed to identify secretory products from macrophages that might be therapeutic targets for limiting the inflammatory accentuation of epithelial to mesenchymal transition in bronchiolitis obliterans syndrome. TNFα, IL-1β and IL-8 are elevated in bronchoalveolar lavage from lung transplant patients prior to diagnosis of bronchiolitis obliterans syndrome. Classically activated macrophages secrete more TNFα and IL-1β than alternatively activated macrophages and dramatically accentuate TGF-β1-driven epithelial to mesenchymal transition in bronchial epithelial cells isolated from lung transplant patients. Blocking TNFα, but not IL-1β, inhibits the accentuation of epithelial to mesenchymal transition. In a pilot unblinded therapeutic intervention in five patients with progressive bronchiolitis obliterans syndrome, anti-TNFα treatment improved forced expiratory volume in 1 second and 6-min walk distances in four patients. Our data identify TNFα as a potential new therapeutic target in bronchiolitis obliterans syndrome deserving of a randomized placebo controlled clinical trial.
AuthorsL A Borthwick, P A Corris, R Mahida, A Walker, A Gardner, M Suwara, G E Johnson, E J Moisey, M Brodlie, C Ward, J D Perry, A De Soyza, D A Mann, A J Fisher
JournalAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (Am J Transplant) Vol. 13 Issue 3 Pg. 621-33 (Mar 2013) ISSN: 1600-6143 [Electronic] United States
PMID23331923 (Publication Type: Case Reports, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Copyright© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Cytokines
  • Transforming Growth Factor beta1
  • Tumor Necrosis Factor-alpha
  • Infliximab
Topics
  • Adolescent
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Bronchiolitis Obliterans (metabolism, pathology, prevention & control)
  • Cytokines (metabolism)
  • Epithelial-Mesenchymal Transition (drug effects)
  • Female
  • Forced Expiratory Volume
  • Graft Rejection (metabolism, pathology, prevention & control)
  • Humans
  • Inflammation (metabolism, pathology, prevention & control)
  • Infliximab
  • Lung Transplantation
  • Macrophage Activation (drug effects)
  • Male
  • Middle Aged
  • Pilot Projects
  • Prognosis
  • Transforming Growth Factor beta1 (pharmacology)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors, metabolism)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: